Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pralsetinib”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Large-scale testing (Phase 3)Ended earlyNCT04222972
What this trial is testing

Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
RET-fusion Non Small Cell Lung CancerLung NeoplasmCarcinoma, Non-Small-Cell Lung+14 more
Hoffmann-La Roche 223
Testing effectiveness (Phase 2)Study completedNCT03037385
What this trial is testing

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more
Hoffmann-La Roche 590
Not applicableApproved For MarketingNCT04204928
What this trial is testing

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid Cancer
Blueprint Medicines Corporation
Large-scale testing (Phase 3)WithdrawnNCT04760288
What this trial is testing

Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

Who this might be right for
Medullary Thyroid Cancer
Hoffmann-La Roche
Not applicableNot Yet RecruitingNCT07418879
What this trial is testing

A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC

Who this might be right for
Non-small Cell Lung CancerRET FusionPralsetinib
Fudan University 25
Not applicableNot Yet RecruitingNCT07048964
What this trial is testing

A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations

Who this might be right for
Medullary Thyroid Cancer (MTC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 40
Not applicableUnknownNCT04697446
What this trial is testing

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Who this might be right for
RET-fusion Non Small Cell Lung CancerLung NeoplasmCarcinoma, Non-Small-Cell Lung+14 more
Blueprint Medicines Corporation 279